Back to search results

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

Abroad (travel likely)RecruitingPHASE3

Conditions

Schizophrenia · Autism-Related Irritability

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Local Institution - 0054, Dothan, Alabama, United States

  • Local Institution - 0163, Phoenix, Arizona, United States

  • Advanced Research Center Inc., Anaheim, California, United States

    Contact: Study coordinator (Steven Macina) · 714-999-6688

  • Local Institution - 0159, Anaheim, California, United States

  • Inland Psychiatric Medical Group., Chino, California, United States

    Contact: Study coordinator (Nandita Puchakayala) · 909-488-9116

  • Local Institution - 0024, Culver City, California, United States

  • Local Institution - 0162, Glendale, California, United States

  • Local Institution - 0153, Los Angeles, California, United States

  • Local Institution - 0158, Orange, California, United States

  • Local Institution - 0083, Redlands, California, United States

  • Local Institution - 0089, San Francisco, California, United States

  • Local Institution - 0157, San Rafael, California, United States

  • Local Institution - 0161, Colorado Springs, Colorado, United States

  • Local Institution - 0154, New Haven, Connecticut, United States

  • Local Institution - 0145, Boca Raton, Florida, United States

  • Local Institution - 0160, Gainesville, Florida, United States

  • Local Institution - 0164, Gainesville, Florida, United States

  • Local Institution - 0168, Hollywood, Florida, United States

  • Local Institution - 0166, Orange City, Florida, United States

  • Apg Research, Llc, Orlando, Florida, United States

    Contact: Study coordinator (Morteza Nadjafi) · 407-423-7149

  • Atlanta Center for Medical Research, Atlanta, Georgia, United States

    Contact: Study coordinator (Elyssa Barron) · 404-881-5800

  • Salveo Integrative Health - Lawrenceville, Lawrenceville, Georgia, United States

    Contact: Study coordinator (Shahzad Hashmi)

  • Denali Health Atlanta, LLC, Stone Mountain, Georgia, United States

    Contact: Study coordinator (Maria Johnson)

  • EmVenio Research Center - Prime Healthcare, Chicago, Illinois, United States

    Contact: Study coordinator (Mitchell Glaser) · 773-620-2995

  • Local Institution - 0076, Boston, Massachusetts, United States

  • Local Institution - 0132, Lexington, Massachusetts, United States

  • Local Institution - 0059, Worcester, Massachusetts, United States

  • Local Institution - 0152, Bloomfield Hills, Michigan, United States

  • Local Institution - 0142, Columbia, Missouri, United States

  • Local Institution - 0147, Lincoln, Nebraska, United States

  • Local Institution - 0144, Las Vegas, Nevada, United States

  • Local Institution - 0146, Neptune City, New Jersey, United States

  • Local Institution - 0061, Great Neck, New York, United States

  • Local Institution - 0156, Staten Island, New York, United States

  • Local Institution - 0151, The Bronx, New York, United States

  • University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States

    Contact: Study coordinator (Melissa DelBello)

  • Local Institution - 0148, Cincinnati, Ohio, United States

  • Local Institution - 0139, West Chester, Ohio, United States

  • Local Institution - 0143, Danville, Pennsylvania, United States

  • Local Institution - 0150, Pittsburgh, Pennsylvania, United States

  • Local Institution - 0137, Nashville, Tennessee, United States

  • Local Institution - 0149, Dallas, Texas, United States

  • VAST Clinical Research, Garland, Texas, United States

    Contact: Study coordinator (Asikaiwe Chima)

  • Local Institution - 0169, Houston, Texas, United States

  • Local Institution - 0165, Plano, Texas, United States

  • Local Institution - 0066, Spring, Texas, United States

  • Local Institution - 0141, Orem, Utah, United States

  • Local Institution - 0140, Provo, Utah, United States

  • Local Institution - 0167, West Point, Utah, United States

  • Local Institution - 0050, Richmond, Virginia, United States

  • Local Institution - 0155, Everett, Washington, United States

  • Local Institution - 0084, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0085, La Plata, Buenos Aires, Argentina

  • Local Institution - 0036, Buenos Aires, Argentina

  • Local Institution - 0035, Córdoba, Argentina

  • Local Institution - 0116, Santiago del Estero, Argentina

  • Local Institution - 0107, Westmead, New South Wales, Australia

  • Local Institution - 0106, Brisbane, Queensland, Australia

  • Local Institution - 0108, Melbourne, Victoria, Australia

  • Local Institution - 0109, Melbourne, Victoria, Australia

  • Local Institution - 0111, Edmonton, Alberta, Canada

  • Local Institution - 0110, Kingston, Ontario, Canada

  • Local Institution - 0113, Toronto, Ontario, Canada

  • Local Institution - 0112, Montreal, Quebec, Canada

  • Local Institution - 0118, Bordeaux, France

  • Local Institution - 0120, Bron, France

  • Local Institution - 0119, Paris, France

  • Local Institution - 0121, Gdansk, Germany

  • Local Institution - 0129, Budapest, Hungary

  • Local Institution - 0130, Gyula, Hungary

  • Local Institution - 0131, Szeged, Hungary

  • Local Institution - 0075, Chikugo, Fukuoka, Japan

  • Goryokai Medical Corporation - Goryokai Hospital, Sapporo, Hokkaido, Japan

    Contact: Study coordinator (Kimihiro Nakajima) · +81-11-771-5660

  • Local Institution - 0025, Zentsujichó, Kagawa-ken, Japan

  • Local Institution - 0062, Miyakonojō, Miyazaki, Japan

  • Local Institution - 0086, Bunkyo-ku, Tokyo, Japan

  • Local Institution - 0056, Ōta-ku, Tokyo, Japan

  • Local Institution - 0063, Yokohama, Kanagawa, Japan

  • Local Institution - 0128, Poznan, Greater Poland Voivodeship, Poland

  • Local Institution - 0125, Wroclaw, Lower Silesian Voivodeship, Poland

  • Local Institution - 0122, Kraśnik, Lublin Voivodeship, Poland

  • Local Institution - 0127, Warsaw, Masovian Voivodeship, Poland

  • Local Institution - 0126, Gdansk, Pomeranian Voivodeship, Poland

  • Local Institution - 0123, Szczecin, West Pomeranian Voivodeship, Poland

  • Local Institution - 0124, Katowice, Poland

  • Local Institution - 0029, Bucharest, Bucharest, Romania

  • Local Institution - 0040, Bucharest, Romania

  • Local Institution - 0042, Bucharest, Romania

  • Cluj Napoca Emergency Hospital for Children, Department of Pediatric Psychiatry, Cluj-Napoca, Romania

    Contact: Study coordinator (Elena Predescu)

  • Local Institution - 0008, Iași, Romania

  • Emergency Clinical Hospital For Children Louis Turcanu Timis, Timișoara, Romania

    Contact: Study coordinator (Laura Nussbaum)

  • Local Institution - 0101, Barcelona, Spain

  • Local Institution - 0099, Barcelona, Spain

  • Local Institution - 0098, Madrid, Spain

  • Local Institution - 0100, Madrid, Spain

Study leads

  • Bristol-Myers Squibb

    Study Director

    Bristol-Myers Squibb

View source on ClinicalTrials.gov(opens in a new tab)